Reasons to Invest

• World-first prebiotic ingredient derived from sugarcane, clinically researched and IP-protected.

• State-of-the-art, German-engineered factory in Australia, built with $10 million in infrastructure and IP, processing 1,000 tonnes per year.

• Backed by 14 FSANZ-approved health claims, 2 TGA-listed medicine ingredient entries, and supported by leading Australian researchers

• Rapid market traction with partnerships in health systems, veterinary networks, and 15 national sports teams, including leading AFL, NRL, Rugby, Netball, and Soccer teams

• Gut health market is projected to reach $270 billion by 2034, with the digestive health products segment already valued at $116.92 billion and continuing to grow rapidly.

• HFS targets the high-growth pet gut health sector, valued at USD 84B and set to reach USD 121B by 2032, with proven animal-specific products like PhyteQuine™ and PhytoCanis™. 

• Established relationships with Provet, which supplies 5,700 veterinary clinics in Australasia, and Covetrus, its parent company and global leader in animal health services, supplying 110,000 clinics worldwide with USD 3.8B in annual sales.

• Partnership & supply agreement with Tismor Health & Wellness, a large Australian manufacturer & blender of gut health market products for Kfibre & White Label Products.

• Beyond the health benefits; PhytoBiome’s natural moisture migration properties offer increased yields and extended shelf life for baked goods manufacturers. 

• Patents granted for Inflammatory Bowel Disease (IBD), Gastro-oesophageal Reflux Disease (GORD), and Non-Alcoholic Fatty Liver Disease (NAFLD submission), plus regulatory compliance (FDA, TGA, FSANZ).

• Monash University Low FODMAP certified, non-GMO, gluten-free, HASTA accredited.

• White label and therapeutic product ranges in development.

Opportunity

The gut health market is projected to reach $270 billion by 2034, with the digestive health products segment already valued at $116.92 billion and continuing to grow rapidly. HFS has developed proven, high-demand products that are already being trialled by 15 leading AFL, NRL, Rugby, Netball, and Soccer teams as well as major hospitals, and veterinary networks across Australasia.

These trials demonstrate Kfibre’s potential to enhance athletic performance, supporting stable energy, faster recovery, stronger immunity, and improved nutrient absorption. By combining clinically validated gut health benefits with tangible performance outcomes, HFS is positioned to become the prebiotic of choice for elite athletes and high-performance programs.

With unique intellectual property, proven efficacy, and the only sugarcane-derived whole-plant prebiotic globally, HFS is positioned to lead this market transformation..
Investors are joining at a pivotal moment, with the infrastructure, regulatory approvals, and clinical validation already in place.

Problem & Solution

Problem:

70% of the immune system resides in the gut; yet digestive disorders are surging. 
50% of Australians experience gut issues annually, while 40% of the global population suffers from functional gastrointestinal disorders (FGIDs). 

In 2017, more than 4.6 billion people were affected by digestive diseases worldwide, with associated disability rising by over 50% in recent decades.

Despite growing awareness, existing fibre products continue to fall short on efficacy, tolerability, and clinical validation, contributing to poor health outcomes and escalating public health costs.
 

Solution:

Health Food Symmetry’s flagship products, PhytoBiome™ (ingredient) and Kfibre™ (retail), are clinically validated to support microbiome nutrition, ease digestive symptoms, and enhance overall well-being. Backed by 14 FSANZ-approved health claims, 2 TGA listed medicine ingredient entries, and supported by leading Australian researchers, Professor Eri of RMIT, they directly address the key gaps in the current fibre market.

HFS also delivers targeted solutions for animals. In the equine sector, digestive supplements now account for over 20% of total sales, with growing uptake in performance and veterinary contexts. The broader animal intestinal health market is projected to grow from USD 4.3 billion to USD 6.7 billion by 2032.

With clinically supported, IP-protected products for both human and animal health, Health Food Symmetry is strategically positioned to lead in this fast-expanding global market.

HFS is also committed to social impact. Through its collaboration with Cooee Cookies, which provides free nutritional cookies to First Nations communities, HFS ingredients add the equivalent of 1-2 servings of vegetables per cookie, helping to make nutritious options more accessible.

Company Structure

Health Food Symmetry is led by an experienced team of founders, scientists, and commercial strategists with deep expertise in functional food manufacturing, regulatory affairs, and clinical product development.

The company owns and operates a state-of-the-art, German-engineered factory in Australia, built with $10 million in infrastructure and trade-secret-protected processes. Strategic partnerships are in place with Tismor Health & Wellness for product blending and Sunrise Health for marketing and distribution.

The business is structured for B2B scale with retail and white-label capabilities, supported by robust accreditations including FDA, TGA, FSANZ, HASTA, Kosher, and Halal certifications.

Business Model

HFS generates revenue through B2B, wholesale, ingredient sales (PhytoBiome™), retail distribution (Kfibre™), and white label formulations. 

It also licenses its formulations and collaborates with leading distributors across the human, animal, and sports health sectors.
With supply agreements secured and active trials underway in hospitals, veterinary clinics, and elite sports teams, HFS is already revenue-generating. Its vertically integrated model ensures full control over production, quality, intellectual property, and margins, enabling scalable and sustainable growth.

Industry & Competitive Advantage

The global gut health market is accelerating toward a projected $270 billion by 2034, driven by rising consumer focus on digestive wellness. The digestive health products sector alone is already valued at $116.92 billion.

In 2024, searches for ‘gut health’ jumped 35%, and ‘microbiome’ rose 31%.

Demand is fueled by rising awareness, urbanisation, dietary changes, rising healthcare costs, and the limitations of traditional fibre products.

In the animal health market, demand for microbiome-targeted products is also accelerating. The pet digestive health sector is expected to grow from $84 billion to $121 billion by 2032, while equine digestive products now account for over 20% of total supplement sales.

One to two servings of Kfibre™ deliver the fibre equivalent of two to four servings of vegetables, offering broad health benefits in a FODMAP-friendly, non-GMO format.

HFS is the only global producer of natural, sugarcane-derived whole-plant prebiotics, backed by full vertical integration, patented applications, and major market approvals. 

With patents in IBD, GORD, and NAFLD, FODMAP certification, and strong distributor networks, HFS offers a clear competitive edge. It is also the only prebiotic worldwide with HASTA accreditation, trusted by elite sports teams and healthcare providers.

Use of Funds

The capital raised will be used to:

• Expand production capacity from 1,000 tonnes to 1,500 tonnes through plant upgrades, including a new decanter centrifuge and electrical infrastructure.

• Launch new prebiotic, probiotic and postbiotic product formulations for targeted gut health solutions.

• Protect and commercialise new IP and clinical research findings.

• Accelerate domestic and international B2B sales and distributor partnerships.

• Support marketing and brand growth through agency engagement and campaign rollouts.

These investments will enable HFS to meet growing demand, improve operating efficiencies, and scale globally.

Risks

Like any investment, there are risks to consider. These include:

• Market Risk: Changes in consumer behaviour or health regulations could affect growth.

• Operational Risk: Delays or challenges in expanding production could impact timelines.

• Competitive Risk: Entry of new players with similar solutions could increase market competition.

HFS is actively mitigating these risks through its strong IP position, vertically integrated operations, robust certifications, and global distributor partnerships.

About Swarmer

Swarmer is an Australian equity crowdfunding platform connecting businesses and investors. Designed to support start-ups, growth companies and scale-ups we allow everyday investors to own a share in businesses that are the future. We hold Australian Financial Services License (AFS License #507867). 

Find out more about becoming a shareholder via Equity Crowdfunding through Swarmer.